Anti-PDL1 Immunotherapy Demonstrates Efficacy in Phase 2 NSCLC Study

Genentech announced that in the large pivotal Phase 2 study, BIRCH, atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumors (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1).

BIRCH is an open-label, multicenter, single-arm Phase 2 study that evaluated the safety and efficacy of atezolizumab in 667 people with locally advanced or metastatic NSCLC whose disease expressed PD-L1. The primary endpoint of the study was ORR. The study showed the amount of PD-L1 expressed by a person's cancer correlated with their response to the drug.

RELATED: Limited Resection Generally Not Equivalent in Stage IA NSCLC

The Food and Drug Administration (FDA) granted atezolizumab Breakthrough Therapy designation earlier this year for the treatment of people whose NSCLC expresses PD-L1 and who progressed during or after standard treatments (e.g., platinum-based chemotherapy and appropriate targeted therapy for EGFR mutation-positive or ALK-positive disease).

For more information call (800) 821–8590 or visit Gene.com.

Loading links....